Altria (MO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria stock has risen 8% this year due to analyst optimism regarding its smoke-free products. However, does the surge make it too costly?
MO is making steady progress in the smoke-free transition, with oral nicotine gaining traction as it reshapes the business focus.
The Dividend Harvesting Portfolio, built with $100/week, now yields 8.04% and has returned 33.22% on invested capital. I am bullish on energy, real estate, and undervalued dividend stocks like OKE and VZ, expecting them to outperform in a lower-rate environment. Portfolio diversification across 41 positions and asset classes has driven consistent income growth, with forward annualized dividend income reaching $2,720.76.
Altria (MO) closed the most recent trading day at $60.15, moving +2.75% from the previous trading session.
Altria Group, Inc. ( MO ), a prominent name in the tobacco and vaping space, has faced notable pressure in recent months, with its shares declining 8.2% over the past three months. This drop stands in stark contrast to the broader market's strength, as the Zacks Tobacco industry advanced 1.7%, the Zacks Consumer Staples sector gained 1.2% and the S&P 500 rallied 6.4% over the same period.
Altria (MO) closed the most recent trading day at $58.54, moving +1.76% from the previous trading session.
MO shifts its cigarette mix toward lower-priced options as consumers become more price-conscious, helping cushion volume pressure in a challenging market.
The S&P 500 booked its third consecutive gain of over 15% in 2025, but it wasn't a banner year for everyone. Some of the market's previous objects of affection treaded water in 2025, especially following the tariff re-rating in April.
Altria remains heavily reliant on traditional cigarettes, with smoke-free products contributing minimally to revenues and earnings. I expect combustible dominance to continue going forward, due to litigation resulting in a sales ban for Altria's vapes, as well as the exploding market for illegally imported flavored products. Oral pouches (on!) also face significant competition from ZYNs (produced by Philip Morris).
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.